Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 34Leukemia 26Lymphoma, Non-Hodgkin 23Lymphoma 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Recurrence 19Leukemia, Lymphocytic, Chronic, B-Cell 19Myelodysplastic Syndromes 18Hematologic Neoplasms 18Melanoma 16Neoplasm Metastasis 15Lymphoma, B-Cell 14Multiple Myeloma 12Pancreatic Neoplasms 11Hodgkin Disease 11Stomach Neoplasms 10Ovarian Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Breast Neoplasms 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma, Mantle-Cell 7Lymphoma, Follicular 7Uterine Cervical Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Neoplasms, Plasma Cell 5Kidney Neoplasms 5Burkitt Lymphoma 5Myeloproliferative Disorders 4

Interventions

pembrolizumab 1fludarabine 1cobimetinib 1TAK-981 1Nivolumab 1Ipilimumab 1Injections 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced or Metastatic Solid Tumors × fludarabine × Clear all
NCT05693844 2024-05-10

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
15 enrolled
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡